source
- Moderna’s stock soars after Phase 3 success of melanoma vaccine with MerckBioPharma Dive’s latest data-visualization series charts Moderna’s dramatic stock rebound in 2026 after a period of decline. The company had struggled when demand for its COVID-19 vaccine fell, pr…
- China drafts policy to block foreign buyouts of key cell-gene therapy and siRNA platformsChina’s government has released a draft amendment to its export blacklist that would prohibit or tightly control foreign purchases of certain biopharmaceutical platforms. The rule targets propriet…